대봉엘에스

078140KOSDAQ의약품 제조업

61.3 / 100

Reference Date: 2026-06-10

Financial Score24.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Plunged 22.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daebong LS, established in 1986, operates across medical beauty and bio sectors, developing safe and effective products aligned with its mission to provide solutions for a healthier, more beautiful life. Key offerings include respiratory treatments, hypertension drugs, and functional cosmetic materials, with consolidated revenue reaching 1,021 billion KRW in 2025, reflecting an 8.6% year-over-year growth.

Number of Employees

138people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.99Industry Average 11.935.0Point

In line with industry avg

PBR

0.52Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

7.05Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio

39.82Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲59.6% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 5.8% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
대봉엘에스, 1분기 매출 291억…전년比 12%↑
대봉엘에스의 1분기 매출이 전년 대비 12% 증가하여 긍정적인 실적을 발표했다.
Positive
'메디컬 뷰티' 앞세운 대봉그룹 계열사 "동반 실적 호조"
대봉엘에스의 해외 매출이 분기 최대 규모로 증가하며 그룹 내 성장을 주도하고 있다.
Positive
대봉엘에스, 'ICI 2026’ 참가…인니 시장 공략 박차
대봉엘에스가 인니 시장 진출을 위한 주요 전시회 참가로 차세대 기능성 소재의 홍보 성공, 긍정적인 시장 반응 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,260Won52-week high 14,89052-week low 8,260

1-month return0.0Point

1m -22.08% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15